BioLineRx Ltd. (BLRX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$2.46

From 52W high−43.99%

Volume2714.00

Market cap$12.06M

P/E (TTM)—

P/S (TTM)10.1x

Div yield—

Key dataSep 18, 2026

Open

$2.46

From 52W high

−43.99%

Volume

2714.00

Market cap

$12.06M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−43.5x

P/E (TTM)

—

RSI (14)

45.4

MomentumView details →

1D Return

−1.70%

YTD Return

−7.22%

SummaryUpdated Jun 1, 2026

BioLineRx Ltd. (NASDAQ:BLRX) is a clinical-stage biopharmaceutical company founded in 2003 and headquartered in Hevel Modi'in, Israel. The company has undergone a significant strategic transformation from a development-focused biotech to a hybrid commercial and development organization. Following FDA approval of its lead drug APHEXDA in September 2023, BioLineRx successfully launched its first commercial product while simultaneously executing a major licensing deal with Ayrmid Pharma in 2024 that fundamentally reshaped its business model and financial profile.

Ask drillr about BioLineRx Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−43.5x

EV/Sales

8.2x

P/S (TTM)

10.1x

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

36.19%

Net Margin

−99.58%

EBITDA Margin

−18.90%

ROE (TTM)

−8.60%

ROA (TTM)

−3.54%

Asset Turnover

0.03x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−50.22%

EPS CAGR 3Y

+93.72%

EBITDA YoY

—

MomentumView details →

1D Return

−1.70%

YTD Return

−7.22%

1Y Return

−31.65%

RSI (14)

45.4

vs 50D SMA

−6.76%

vs 200D SMA

−10.20%

Capital & dividendView details →

Debt/Equity

0.58x

Current Ratio

1.20x

Quick Ratio

1.04x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.77

EPS Surprise

−413.33%

Beats (12Q)

7/12

Next Q EPS Est

−$0.39

Avg Surprise (4Q)

−67.40%

Rev Surprise

−41.20%

Financials snapshotView financials →

Revenue (TTM)

1.40M

Net Income (TTM)

−8.03M

Op. CF (TTM)

—

Next earningsNov 23, 2026 →

Latest newsMore news →

BioLineRx reported its unaudited financial results for the quarter ended June 30, 2026, and provided a corporate update.20d ago

BioLineRx Ltd. announced a registered direct offering and concurrent private placement of 1,348,921 American Depositary Shares at $2.78 per ADS, raising approximately $3.75 million.23d ago

Similar companies

Aspire Biopharma Holdings, Inc.ASBP Phio Pharmaceuticals Corp.PHIO Kiora Pharmaceuticals, Inc.KPRX Anebulo Pharmaceuticals, Inc.ANEB Medicus Pharma Ltd. Common StockMDCX Cuprina Holdings (Cayman) Limited Class A Ordinary SharesCUPR Find similar companies →

Latest newsMore news →

BioLineRx reported its unaudited financial results for the quarter ended June 30, 2026, and provided a corporate update.20d ago BioLineRx Ltd. announced a registered direct offering and concurrent private placement of 1,348,921 American Depositary Shares at $2.78 per ADS, raising approximately $3.75 million.23d ago